Sanofi stops development of Nurix-partnered immune drug

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 04 Nov, 17:18 UTC

The decision sparked a sell-off in Nurix shares as well as analyst debate about the prospects of drugs designed to degrade a tough-to-reach protein called STAT6.

science

Sources

• T2Sanofi stops development of Nurix-partnered immune drugBioPharma Dive / Healthcare Dive / MedTech Dive04 Nov, 17:18